nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—SLC22A2—Progesterone—uterine cancer	0.232	0.535	CbGbCtD
Amiloride—SLC22A1—Progesterone—uterine cancer	0.202	0.465	CbGbCtD
Amiloride—SLC9A1—exocrine gland—uterine cancer	0.0111	0.0448	CbGeAlD
Amiloride—ASIC2—endometrium—uterine cancer	0.00713	0.0288	CbGeAlD
Amiloride—AOC1—Tryptophan metabolism—CYP19A1—uterine cancer	0.00588	0.058	CbGpPWpGaD
Amiloride—PLAU—myometrium—uterine cancer	0.00581	0.0235	CbGeAlD
Amiloride—PLAU—Endochondral Ossification—CDKN1C—uterine cancer	0.00544	0.0536	CbGpPWpGaD
Amiloride—SCNN1D—epithelium—uterine cancer	0.00512	0.0207	CbGeAlD
Amiloride—SCNN1G—uterine cervix—uterine cancer	0.00508	0.0205	CbGeAlD
Amiloride—SLC9A1—epithelium—uterine cancer	0.00481	0.0195	CbGeAlD
Amiloride—SLC9A1—uterine cervix—uterine cancer	0.00477	0.0193	CbGeAlD
Amiloride—SCNN1G—renal system—uterine cancer	0.00475	0.0192	CbGeAlD
Amiloride—AOC1—decidua—uterine cancer	0.00475	0.0192	CbGeAlD
Amiloride—AOC1—renal system—uterine cancer	0.00466	0.0189	CbGeAlD
Amiloride—SLC9A1—smooth muscle tissue—uterine cancer	0.00464	0.0188	CbGeAlD
Amiloride—SCNN1G—endometrium—uterine cancer	0.00459	0.0186	CbGeAlD
Amiloride—PLAU—epithelium—uterine cancer	0.00456	0.0185	CbGeAlD
Amiloride—PLAU—uterine cervix—uterine cancer	0.00452	0.0183	CbGeAlD
Amiloride—AOC1—endometrium—uterine cancer	0.00451	0.0182	CbGeAlD
Amiloride—SLC9A1—renal system—uterine cancer	0.00447	0.0181	CbGeAlD
Amiloride—SCNN1G—mammalian vulva—uterine cancer	0.00444	0.018	CbGeAlD
Amiloride—PLAU—smooth muscle tissue—uterine cancer	0.0044	0.0178	CbGeAlD
Amiloride—AOC1—mammalian vulva—uterine cancer	0.00436	0.0176	CbGeAlD
Amiloride—SCNN1B—epithelium—uterine cancer	0.00433	0.0175	CbGeAlD
Amiloride—PLAU—decidua—uterine cancer	0.00431	0.0174	CbGeAlD
Amiloride—SCNN1B—uterine cervix—uterine cancer	0.00429	0.0174	CbGeAlD
Amiloride—PLAU—renal system—uterine cancer	0.00423	0.0171	CbGeAlD
Amiloride—PLAU—endometrium—uterine cancer	0.00409	0.0166	CbGeAlD
Amiloride—SCNN1B—decidua—uterine cancer	0.00409	0.0165	CbGeAlD
Amiloride—SCNN1B—renal system—uterine cancer	0.00401	0.0162	CbGeAlD
Amiloride—SCNN1A—epithelium—uterine cancer	0.004	0.0162	CbGeAlD
Amiloride—SCNN1A—uterine cervix—uterine cancer	0.00396	0.016	CbGeAlD
Amiloride—PLAU—mammalian vulva—uterine cancer	0.00396	0.016	CbGeAlD
Amiloride—SCNN1B—endometrium—uterine cancer	0.00388	0.0157	CbGeAlD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—DCN—uterine cancer	0.00387	0.0381	CbGpPWpGaD
Amiloride—SCNN1D—female reproductive system—uterine cancer	0.0038	0.0154	CbGeAlD
Amiloride—SCNN1G—female reproductive system—uterine cancer	0.0038	0.0154	CbGeAlD
Amiloride—SCNN1A—decidua—uterine cancer	0.00378	0.0153	CbGeAlD
Amiloride—PLAU—uterus—uterine cancer	0.00377	0.0153	CbGeAlD
Amiloride—SCNN1B—mammalian vulva—uterine cancer	0.00375	0.0152	CbGeAlD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MAP3K4—uterine cancer	0.00375	0.0369	CbGpPWpGaD
Amiloride—AOC1—female reproductive system—uterine cancer	0.00373	0.0151	CbGeAlD
Amiloride—ASIC1—female reproductive system—uterine cancer	0.00373	0.0151	CbGeAlD
Amiloride—SCNN1A—renal system—uterine cancer	0.00371	0.015	CbGeAlD
Amiloride—SLC9A1—female reproductive system—uterine cancer	0.00358	0.0145	CbGeAlD
Amiloride—SCNN1A—mammalian vulva—uterine cancer	0.00347	0.014	CbGeAlD
Amiloride—SCNN1G—vagina—uterine cancer	0.00344	0.0139	CbGeAlD
Amiloride—ASIC1—female gonad—uterine cancer	0.0034	0.0138	CbGeAlD
Amiloride—PLAU—female reproductive system—uterine cancer	0.00339	0.0137	CbGeAlD
Amiloride—AOC1—vagina—uterine cancer	0.00338	0.0137	CbGeAlD
Amiloride—SCNN1A—uterus—uterine cancer	0.0033	0.0134	CbGeAlD
Amiloride—SLC9A1—female gonad—uterine cancer	0.00325	0.0132	CbGeAlD
Amiloride—SCNN1B—female reproductive system—uterine cancer	0.00321	0.013	CbGeAlD
Amiloride—PLAU—female gonad—uterine cancer	0.00308	0.0125	CbGeAlD
Amiloride—PLAU—vagina—uterine cancer	0.00307	0.0124	CbGeAlD
Amiloride—SCNN1A—female reproductive system—uterine cancer	0.00297	0.012	CbGeAlD
Amiloride—SCNN1B—vagina—uterine cancer	0.00291	0.0118	CbGeAlD
Amiloride—SCNN1A—female gonad—uterine cancer	0.0027	0.0109	CbGeAlD
Amiloride—PLAU—E2F transcription factor network—RRM2—uterine cancer	0.00232	0.0228	CbGpPWpGaD
Amiloride—SCNN1D—lymph node—uterine cancer	0.00223	0.00901	CbGeAlD
Amiloride—AOC1—lymph node—uterine cancer	0.00218	0.00884	CbGeAlD
Amiloride—ASIC1—lymph node—uterine cancer	0.00218	0.00884	CbGeAlD
Amiloride—PLAU—Senescence and Autophagy in Cancer—INHBA—uterine cancer	0.00216	0.0213	CbGpPWpGaD
Amiloride—SLC9A1—lymph node—uterine cancer	0.00209	0.00847	CbGeAlD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—ESR1—uterine cancer	0.00208	0.0205	CbGpPWpGaD
Amiloride—SLC22A4—myometrium—uterine cancer	0.00204	0.00826	CbGeAlD
Amiloride—SLC22A2—renal system—uterine cancer	0.002	0.0081	CbGeAlD
Amiloride—PLAU—lymph node—uterine cancer	0.00198	0.00803	CbGeAlD
Amiloride—SCNN1B—lymph node—uterine cancer	0.00188	0.00761	CbGeAlD
Amiloride—SCNN1A—lymph node—uterine cancer	0.00174	0.00703	CbGeAlD
Amiloride—PLAU—ATF-2 transcription factor network—SOCS3—uterine cancer	0.00173	0.017	CbGpPWpGaD
Amiloride—SLC9A1—Defective B3GAT3 causes JDSSDHD—DCN—uterine cancer	0.00169	0.0166	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—uterine cancer	0.00158	0.0155	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—FGFR2—uterine cancer	0.00155	0.0153	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—YWHAE—uterine cancer	0.00154	0.0152	CbGpPWpGaD
Amiloride—SLC22A4—decidua—uterine cancer	0.00151	0.00612	CbGeAlD
Amiloride—PLAU—Endochondral Ossification—IGF1R—uterine cancer	0.00151	0.0148	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—IRF1—uterine cancer	0.00149	0.0147	CbGpPWpGaD
Amiloride—SLC22A4—renal system—uterine cancer	0.00149	0.00601	CbGeAlD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HMGA1—uterine cancer	0.00146	0.0144	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.00144	0.0142	CbGpPWpGaD
Amiloride—SLC22A4—endometrium—uterine cancer	0.00144	0.00581	CbGeAlD
Amiloride—SLC22A1—renal system—uterine cancer	0.00141	0.00572	CbGeAlD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—uterine cancer	0.00138	0.0136	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—MET—uterine cancer	0.00133	0.0131	CbGpPWpGaD
Amiloride—Jaundice—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.00579	CcSEcCtD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—uterine cancer	0.00125	0.0123	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—ESR1—uterine cancer	0.00123	0.0122	CbGpPWpGaD
Amiloride—Visual impairment—Progesterone—uterine cancer	0.00123	0.00567	CcSEcCtD
Amiloride—Tinnitus—Progesterone—uterine cancer	0.00119	0.00548	CcSEcCtD
Amiloride—SLC22A4—female reproductive system—uterine cancer	0.00119	0.00481	CbGeAlD
Amiloride—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00543	CcSEcCtD
Amiloride—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00536	CcSEcCtD
Amiloride—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00533	CcSEcCtD
Amiloride—SLC9A1—RhoA signaling pathway—CDKN1B—uterine cancer	0.00116	0.0114	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—CDH1—uterine cancer	0.00115	0.0114	CbGpPWpGaD
Amiloride—Alopecia—Progesterone—uterine cancer	0.00113	0.0052	CcSEcCtD
Amiloride—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.00112	0.00514	CcSEcCtD
Amiloride—Flatulence—Progesterone—uterine cancer	0.0011	0.00505	CcSEcCtD
Amiloride—SCNN1A—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.0011	0.0108	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.0011	0.0108	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.0011	0.0108	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.0011	0.0108	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.0011	0.0108	CbGpPWpGaD
Amiloride—Tension—Progesterone—uterine cancer	0.00109	0.00502	CcSEcCtD
Amiloride—Nervousness—Progesterone—uterine cancer	0.00108	0.00497	CcSEcCtD
Amiloride—Tinnitus—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.00497	CcSEcCtD
Amiloride—Back pain—Progesterone—uterine cancer	0.00108	0.00495	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—ESR1—uterine cancer	0.00108	0.0106	CbGpPWpGaD
Amiloride—SLC22A4—vagina—uterine cancer	0.00108	0.00435	CbGeAlD
Amiloride—Muscle spasms—Progesterone—uterine cancer	0.00107	0.00492	CcSEcCtD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—uterine cancer	0.00107	0.0105	CbGpPWpGaD
Amiloride—SLC9A1—RhoA signaling pathway—PTEN—uterine cancer	0.00106	0.0105	CbGpPWpGaD
Amiloride—Neutropenia—Dactinomycin—uterine cancer	0.00106	0.00486	CcSEcCtD
Amiloride—Tremor—Progesterone—uterine cancer	0.00104	0.0048	CcSEcCtD
Amiloride—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.00102	0.00471	CcSEcCtD
Amiloride—SLC22A1—vagina—uterine cancer	0.00102	0.00415	CbGeAlD
Amiloride—PLAU—Senescence and Autophagy in Cancer—IGF1R—uterine cancer	0.00101	0.00999	CbGpPWpGaD
Amiloride—Vertigo—Progesterone—uterine cancer	0.001	0.0046	CcSEcCtD
Amiloride—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.000995	0.00457	CcSEcCtD
Amiloride—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00099	0.00455	CcSEcCtD
Amiloride—Palpitations—Progesterone—uterine cancer	0.000984	0.00452	CcSEcCtD
Amiloride—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00098	0.00451	CcSEcCtD
Amiloride—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000976	0.00449	CcSEcCtD
Amiloride—Cough—Progesterone—uterine cancer	0.000972	0.00447	CcSEcCtD
Amiloride—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00097	0.00446	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—SMAD3—uterine cancer	0.000954	0.00939	CbGpPWpGaD
Amiloride—Arthralgia—Progesterone—uterine cancer	0.000948	0.00436	CcSEcCtD
Amiloride—Chest pain—Progesterone—uterine cancer	0.000948	0.00436	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CCL2—uterine cancer	0.000948	0.00933	CbGpPWpGaD
Amiloride—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000946	0.00435	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—SMAD3—uterine cancer	0.000926	0.00912	CbGpPWpGaD
Amiloride—Confusional state—Progesterone—uterine cancer	0.000917	0.00421	CcSEcCtD
Amiloride—PLAU—Osteopontin-mediated events—PIK3CA—uterine cancer	0.000912	0.00898	CbGpPWpGaD
Amiloride—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000907	0.00417	CcSEcCtD
Amiloride—SLC9A1—Carbohydrate metabolism—DCN—uterine cancer	0.000905	0.00891	CbGpPWpGaD
Amiloride—PLAU—Beta3 integrin cell surface interactions—VEGFA—uterine cancer	0.000899	0.00885	CbGpPWpGaD
Amiloride—Shock—Progesterone—uterine cancer	0.000894	0.00411	CcSEcCtD
Amiloride—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.000892	0.0041	CcSEcCtD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	0.000888	0.00874	CbGpPWpGaD
Amiloride—Anorexia—Progesterone—uterine cancer	0.000866	0.00398	CcSEcCtD
Amiloride—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000859	0.00395	CcSEcCtD
Amiloride—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000859	0.00395	CcSEcCtD
Amiloride—PLAU—ATF-2 transcription factor network—CXCL8—uterine cancer	0.000859	0.00846	CbGpPWpGaD
Amiloride—Cramp muscle—Etoposide—uterine cancer	0.000852	0.00392	CcSEcCtD
Amiloride—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.000831	0.00382	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000828	0.00381	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CDKN2A—uterine cancer	0.000826	0.00814	CbGpPWpGaD
Amiloride—Insomnia—Progesterone—uterine cancer	0.000822	0.00378	CcSEcCtD
Amiloride—Paraesthesia—Progesterone—uterine cancer	0.000816	0.00375	CcSEcCtD
Amiloride—Dyspnoea—Progesterone—uterine cancer	0.00081	0.00373	CcSEcCtD
Amiloride—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00081	0.00373	CcSEcCtD
Amiloride—Somnolence—Progesterone—uterine cancer	0.000808	0.00371	CcSEcCtD
Amiloride—Dyspepsia—Progesterone—uterine cancer	0.0008	0.00368	CcSEcCtD
Amiloride—Alopecia—Dactinomycin—uterine cancer	0.000799	0.00367	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—CDKN2A—uterine cancer	0.000799	0.00787	CbGpPWpGaD
Amiloride—Decreased appetite—Progesterone—uterine cancer	0.00079	0.00363	CcSEcCtD
Amiloride—Hyperuricaemia—Epirubicin—uterine cancer	0.000788	0.00362	CcSEcCtD
Amiloride—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000785	0.00361	CcSEcCtD
Amiloride—Gastrointestinal disorder—Progesterone—uterine cancer	0.000785	0.00361	CcSEcCtD
Amiloride—Fatigue—Progesterone—uterine cancer	0.000784	0.0036	CcSEcCtD
Amiloride—Pain—Progesterone—uterine cancer	0.000777	0.00357	CcSEcCtD
Amiloride—Constipation—Progesterone—uterine cancer	0.000777	0.00357	CcSEcCtD
Amiloride—Neutropenia—Etoposide—uterine cancer	0.000765	0.00352	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—FGFR2—uterine cancer	0.000762	0.00751	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00075	0.00345	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CXCL8—uterine cancer	0.000749	0.00738	CbGpPWpGaD
Amiloride—Feeling abnormal—Progesterone—uterine cancer	0.000749	0.00344	CcSEcCtD
Amiloride—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000745	0.00342	CcSEcCtD
Amiloride—Blood uric acid increased—Epirubicin—uterine cancer	0.000744	0.00342	CcSEcCtD
Amiloride—Gastrointestinal pain—Progesterone—uterine cancer	0.000743	0.00342	CcSEcCtD
Amiloride—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00074	0.0034	CcSEcCtD
Amiloride—Neck pain—Epirubicin—uterine cancer	0.000739	0.0034	CcSEcCtD
Amiloride—PLAU—ATF-2 transcription factor network—EP300—uterine cancer	0.000737	0.00726	CbGpPWpGaD
Amiloride—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000734	0.00338	CcSEcCtD
Amiloride—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000732	0.00337	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CDKN1B—uterine cancer	0.000732	0.00721	CbGpPWpGaD
Amiloride—Hepatocellular injury—Epirubicin—uterine cancer	0.000731	0.00336	CcSEcCtD
Amiloride—Hyperuricaemia—Doxorubicin—uterine cancer	0.000729	0.00335	CcSEcCtD
Amiloride—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000725	0.00333	CcSEcCtD
Amiloride—SLC9A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000722	0.00711	CbGpPWpGaD
Amiloride—Abdominal pain—Progesterone—uterine cancer	0.000719	0.0033	CcSEcCtD
Amiloride—Hyperkalaemia—Epirubicin—uterine cancer	0.000718	0.0033	CcSEcCtD
Amiloride—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000716	0.00329	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway—CTNNB1—uterine cancer	0.000716	0.00705	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000711	0.00327	CcSEcCtD
Amiloride—Jaundice—Etoposide—uterine cancer	0.000711	0.00327	CcSEcCtD
Amiloride—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00071	0.00326	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—CDKN1B—uterine cancer	0.000708	0.00697	CbGpPWpGaD
Amiloride—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000704	0.00324	CcSEcCtD
Amiloride—SLC22A4—lymph node—uterine cancer	0.000696	0.00282	CbGeAlD
Amiloride—PLAU—AP-1 transcription factor network—CTNNB1—uterine cancer	0.000691	0.00681	CbGpPWpGaD
Amiloride—Blood uric acid increased—Doxorubicin—uterine cancer	0.000688	0.00316	CcSEcCtD
Amiloride—Aplastic anaemia—Epirubicin—uterine cancer	0.000686	0.00315	CcSEcCtD
Amiloride—Neck pain—Doxorubicin—uterine cancer	0.000684	0.00315	CcSEcCtD
Amiloride—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000679	0.00312	CcSEcCtD
Amiloride—Hepatocellular injury—Doxorubicin—uterine cancer	0.000676	0.00311	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—PTEN—uterine cancer	0.000674	0.00664	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000674	0.0031	CcSEcCtD
Amiloride—Coma—Epirubicin—uterine cancer	0.000668	0.00307	CcSEcCtD
Amiloride—Hyperkalaemia—Doxorubicin—uterine cancer	0.000664	0.00305	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—VEGFA—uterine cancer	0.000654	0.00644	CbGpPWpGaD
Amiloride—Asthenia—Progesterone—uterine cancer	0.000652	0.003	CcSEcCtD
Amiloride—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000651	0.00299	CcSEcCtD
Amiloride—Pruritus—Progesterone—uterine cancer	0.000643	0.00296	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—EP300—uterine cancer	0.000643	0.00633	CbGpPWpGaD
Amiloride—PLAU—Beta1 integrin cell surface interactions—VEGFA—uterine cancer	0.000638	0.00628	CbGpPWpGaD
Amiloride—Aplastic anaemia—Doxorubicin—uterine cancer	0.000635	0.00292	CcSEcCtD
Amiloride—Diarrhoea—Progesterone—uterine cancer	0.000622	0.00286	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—EP300—uterine cancer	0.000621	0.00612	CbGpPWpGaD
Amiloride—Coma—Doxorubicin—uterine cancer	0.000618	0.00284	CcSEcCtD
Amiloride—Anorexia—Dactinomycin—uterine cancer	0.000612	0.00282	CcSEcCtD
Amiloride—Hepatic function abnormal—Epirubicin—uterine cancer	0.000607	0.00279	CcSEcCtD
Amiloride—Dizziness—Progesterone—uterine cancer	0.000601	0.00276	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN2A—uterine cancer	0.000597	0.00588	CbGpPWpGaD
Amiloride—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000591	0.00272	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000585	0.00269	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—PIK3CA—uterine cancer	0.000585	0.00576	CbGpPWpGaD
Amiloride—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000583	0.00268	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN2A—uterine cancer	0.00058	0.00571	CbGpPWpGaD
Amiloride—Alopecia—Etoposide—uterine cancer	0.000578	0.00266	CcSEcCtD
Amiloride—Vomiting—Progesterone—uterine cancer	0.000578	0.00266	CcSEcCtD
Amiloride—Rash—Progesterone—uterine cancer	0.000573	0.00263	CcSEcCtD
Amiloride—Dermatitis—Progesterone—uterine cancer	0.000573	0.00263	CcSEcCtD
Amiloride—Headache—Progesterone—uterine cancer	0.000569	0.00262	CcSEcCtD
Amiloride—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000564	0.00259	CcSEcCtD
Amiloride—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000562	0.00258	CcSEcCtD
Amiloride—Decreased appetite—Dactinomycin—uterine cancer	0.000559	0.00257	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—ERBB2—uterine cancer	0.000554	0.00546	CbGpPWpGaD
Amiloride—Fatigue—Dactinomycin—uterine cancer	0.000554	0.00255	CcSEcCtD
Amiloride—Back pain—Etoposide—uterine cancer	0.000551	0.00253	CcSEcCtD
Amiloride—Pain—Dactinomycin—uterine cancer	0.000549	0.00253	CcSEcCtD
Amiloride—Muscle spasms—Etoposide—uterine cancer	0.000548	0.00252	CcSEcCtD
Amiloride—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000545	0.0025	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CXCL8—uterine cancer	0.000542	0.00534	CbGpPWpGaD
Amiloride—Nausea—Progesterone—uterine cancer	0.00054	0.00248	CcSEcCtD
Amiloride—Hyponatraemia—Epirubicin—uterine cancer	0.000532	0.00245	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—NRAS—uterine cancer	0.000531	0.00523	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—HRAS—uterine cancer	0.00053	0.00522	CbGpPWpGaD
Amiloride—Pain in extremity—Epirubicin—uterine cancer	0.00053	0.00244	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.00053	0.00244	CcSEcCtD
Amiloride—Feeling abnormal—Dactinomycin—uterine cancer	0.000529	0.00243	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN1B—uterine cancer	0.000529	0.00521	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000525	0.00242	CcSEcCtD
Amiloride—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000524	0.00241	CcSEcCtD
Amiloride—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000519	0.00239	CcSEcCtD
Amiloride—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000519	0.00239	CcSEcCtD
Amiloride—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000516	0.00237	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN1B—uterine cancer	0.000513	0.00506	CbGpPWpGaD
Amiloride—Vertigo—Etoposide—uterine cancer	0.000512	0.00235	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CTNNB1—uterine cancer	0.000511	0.00504	CbGpPWpGaD
Amiloride—Abdominal pain—Dactinomycin—uterine cancer	0.000508	0.00233	CcSEcCtD
Amiloride—Cough—Etoposide—uterine cancer	0.000497	0.00229	CcSEcCtD
Amiloride—Hyponatraemia—Doxorubicin—uterine cancer	0.000493	0.00226	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000491	0.00226	CcSEcCtD
Amiloride—Pain in extremity—Doxorubicin—uterine cancer	0.000491	0.00226	CcSEcCtD
Amiloride—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.00225	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—PTEN—uterine cancer	0.000487	0.0048	CbGpPWpGaD
Amiloride—Chest pain—Etoposide—uterine cancer	0.000485	0.00223	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CTNNB1—uterine cancer	0.000485	0.00478	CbGpPWpGaD
Amiloride—Orthostatic hypotension—Epirubicin—uterine cancer	0.000484	0.00223	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—NRAS—uterine cancer	0.000482	0.00475	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—AKT1—uterine cancer	0.000478	0.00471	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—EP300—uterine cancer	0.000475	0.00468	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PTEN—uterine cancer	0.000473	0.00466	CbGpPWpGaD
Amiloride—Confusional state—Etoposide—uterine cancer	0.000469	0.00216	CcSEcCtD
Amiloride—SLC9A1—Endothelins—AKT1—uterine cancer	0.000468	0.00461	CbGpPWpGaD
Amiloride—Muscular weakness—Epirubicin—uterine cancer	0.000468	0.00215	CcSEcCtD
Amiloride—SLC9A1—Metabolism—NDUFB11—uterine cancer	0.000468	0.00461	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—SRD5A2—uterine cancer	0.000468	0.00461	CbGpPWpGaD
Amiloride—Abdominal distension—Epirubicin—uterine cancer	0.000461	0.00212	CcSEcCtD
Amiloride—Asthenia—Dactinomycin—uterine cancer	0.000461	0.00212	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TP53—uterine cancer	0.00046	0.00453	CbGpPWpGaD
Amiloride—SLC9A1—G Protein Signaling Pathways—KRAS—uterine cancer	0.000457	0.0045	CbGpPWpGaD
Amiloride—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000448	0.00206	CcSEcCtD
Amiloride—Angina pectoris—Epirubicin—uterine cancer	0.000447	0.00205	CcSEcCtD
Amiloride—Anorexia—Etoposide—uterine cancer	0.000443	0.00204	CcSEcCtD
Amiloride—Diarrhoea—Dactinomycin—uterine cancer	0.00044	0.00202	CcSEcCtD
Amiloride—SLC9A1—Disease—AKR1B10—uterine cancer	0.000434	0.00428	CbGpPWpGaD
Amiloride—Muscular weakness—Doxorubicin—uterine cancer	0.000433	0.00199	CcSEcCtD
Amiloride—Neutropenia—Epirubicin—uterine cancer	0.000429	0.00197	CcSEcCtD
Amiloride—Dysuria—Epirubicin—uterine cancer	0.000429	0.00197	CcSEcCtD
Amiloride—Abdominal distension—Doxorubicin—uterine cancer	0.000427	0.00196	CcSEcCtD
Amiloride—Pollakiuria—Epirubicin—uterine cancer	0.000423	0.00195	CcSEcCtD
Amiloride—PLAU—Hemostasis—IRF1—uterine cancer	0.000423	0.00416	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—NRAS—uterine cancer	0.000422	0.00415	CbGpPWpGaD
Amiloride—Paraesthesia—Etoposide—uterine cancer	0.000418	0.00192	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—AKT1—uterine cancer	0.000417	0.00411	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—KRAS—uterine cancer	0.000415	0.00408	CbGpPWpGaD
Amiloride—Dyspnoea—Etoposide—uterine cancer	0.000415	0.00191	CcSEcCtD
Amiloride—Somnolence—Etoposide—uterine cancer	0.000413	0.0019	CcSEcCtD
Amiloride—Angina pectoris—Doxorubicin—uterine cancer	0.000413	0.0019	CcSEcCtD
Amiloride—Vomiting—Dactinomycin—uterine cancer	0.000409	0.00188	CcSEcCtD
Amiloride—Rash—Dactinomycin—uterine cancer	0.000405	0.00186	CcSEcCtD
Amiloride—Decreased appetite—Etoposide—uterine cancer	0.000404	0.00186	CcSEcCtD
Amiloride—Gastrointestinal disorder—Etoposide—uterine cancer	0.000401	0.00185	CcSEcCtD
Amiloride—Fatigue—Etoposide—uterine cancer	0.000401	0.00184	CcSEcCtD
Amiloride—Jaundice—Epirubicin—uterine cancer	0.000398	0.00183	CcSEcCtD
Amiloride—Pain—Etoposide—uterine cancer	0.000398	0.00183	CcSEcCtD
Amiloride—Constipation—Etoposide—uterine cancer	0.000398	0.00183	CcSEcCtD
Amiloride—Dysuria—Doxorubicin—uterine cancer	0.000397	0.00182	CcSEcCtD
Amiloride—Neutropenia—Doxorubicin—uterine cancer	0.000397	0.00182	CcSEcCtD
Amiloride—Pollakiuria—Doxorubicin—uterine cancer	0.000392	0.0018	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—HRAS—uterine cancer	0.000388	0.00383	CbGpPWpGaD
Amiloride—Feeling abnormal—Etoposide—uterine cancer	0.000383	0.00176	CcSEcCtD
Amiloride—Nausea—Dactinomycin—uterine cancer	0.000382	0.00175	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—PIK3CA—uterine cancer	0.000381	0.00375	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Etoposide—uterine cancer	0.00038	0.00175	CcSEcCtD
Amiloride—Bradycardia—Epirubicin—uterine cancer	0.000374	0.00172	CcSEcCtD
Amiloride—Haemoglobin—Epirubicin—uterine cancer	0.000369	0.0017	CcSEcCtD
Amiloride—Jaundice—Doxorubicin—uterine cancer	0.000369	0.00169	CcSEcCtD
Amiloride—Abdominal pain—Etoposide—uterine cancer	0.000368	0.00169	CcSEcCtD
Amiloride—Haemorrhage—Epirubicin—uterine cancer	0.000367	0.00169	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—NRAS—uterine cancer	0.000364	0.00359	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—KRAS—uterine cancer	0.000363	0.00358	CbGpPWpGaD
Amiloride—SLC9A1—Disease—RNF43—uterine cancer	0.00036	0.00354	CbGpPWpGaD
Amiloride—Visual impairment—Epirubicin—uterine cancer	0.000354	0.00163	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—HRAS—uterine cancer	0.000352	0.00347	CbGpPWpGaD
Amiloride—Bradycardia—Doxorubicin—uterine cancer	0.000346	0.00159	CcSEcCtD
Amiloride—Tinnitus—Epirubicin—uterine cancer	0.000342	0.00157	CcSEcCtD
Amiloride—Haemoglobin—Doxorubicin—uterine cancer	0.000341	0.00157	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—uterine cancer	0.00034	0.00335	CbGpPWpGaD
Amiloride—Haemorrhage—Doxorubicin—uterine cancer	0.000339	0.00156	CcSEcCtD
Amiloride—SLC9A1—Metabolism—STAR—uterine cancer	0.000338	0.00333	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—AKR1B1—uterine cancer	0.000338	0.00333	CbGpPWpGaD
Amiloride—Asthenia—Etoposide—uterine cancer	0.000334	0.00153	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PIK3CA—uterine cancer	0.000334	0.00328	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—uterine cancer	0.000332	0.00327	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.00033	0.00325	CbGpPWpGaD
Amiloride—Pruritus—Etoposide—uterine cancer	0.000329	0.00151	CcSEcCtD
Amiloride—Visual impairment—Doxorubicin—uterine cancer	0.000327	0.0015	CcSEcCtD
Amiloride—Alopecia—Epirubicin—uterine cancer	0.000324	0.00149	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—uterine cancer	0.000323	0.00318	CbGpPWpGaD
Amiloride—Diarrhoea—Etoposide—uterine cancer	0.000318	0.00146	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HRAS—uterine cancer	0.000318	0.00313	CbGpPWpGaD
Amiloride—Tinnitus—Doxorubicin—uterine cancer	0.000317	0.00146	CcSEcCtD
Amiloride—Flatulence—Epirubicin—uterine cancer	0.000315	0.00145	CcSEcCtD
Amiloride—Tension—Epirubicin—uterine cancer	0.000313	0.00144	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—KRAS—uterine cancer	0.000313	0.00309	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—AKT1—uterine cancer	0.000311	0.00307	CbGpPWpGaD
Amiloride—Nervousness—Epirubicin—uterine cancer	0.00031	0.00143	CcSEcCtD
Amiloride—Back pain—Epirubicin—uterine cancer	0.000309	0.00142	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—HRAS—uterine cancer	0.000309	0.00304	CbGpPWpGaD
Amiloride—Dizziness—Etoposide—uterine cancer	0.000308	0.00141	CcSEcCtD
Amiloride—Muscle spasms—Epirubicin—uterine cancer	0.000307	0.00141	CcSEcCtD
Amiloride—Alopecia—Doxorubicin—uterine cancer	0.0003	0.00138	CcSEcCtD
Amiloride—SLC9A1—Disease—AKR1C1—uterine cancer	0.000296	0.00292	CbGpPWpGaD
Amiloride—Vomiting—Etoposide—uterine cancer	0.000296	0.00136	CcSEcCtD
Amiloride—Rash—Etoposide—uterine cancer	0.000293	0.00135	CcSEcCtD
Amiloride—Dermatitis—Etoposide—uterine cancer	0.000293	0.00135	CcSEcCtD
Amiloride—Headache—Etoposide—uterine cancer	0.000291	0.00134	CcSEcCtD
Amiloride—Flatulence—Doxorubicin—uterine cancer	0.000291	0.00134	CcSEcCtD
Amiloride—SLC22A2—Neuronal System—ABCC9—uterine cancer	0.000291	0.00286	CbGpPWpGaD
Amiloride—Tension—Doxorubicin—uterine cancer	0.00029	0.00133	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PIK3CA—uterine cancer	0.000288	0.00284	CbGpPWpGaD
Amiloride—Nervousness—Doxorubicin—uterine cancer	0.000287	0.00132	CcSEcCtD
Amiloride—Vertigo—Epirubicin—uterine cancer	0.000287	0.00132	CcSEcCtD
Amiloride—Back pain—Doxorubicin—uterine cancer	0.000286	0.00131	CcSEcCtD
Amiloride—Muscle spasms—Doxorubicin—uterine cancer	0.000284	0.00131	CcSEcCtD
Amiloride—Palpitations—Epirubicin—uterine cancer	0.000282	0.0013	CcSEcCtD
Amiloride—Cough—Epirubicin—uterine cancer	0.000279	0.00128	CcSEcCtD
Amiloride—Nausea—Etoposide—uterine cancer	0.000276	0.00127	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—AKT1—uterine cancer	0.000272	0.00268	CbGpPWpGaD
Amiloride—Arthralgia—Epirubicin—uterine cancer	0.000272	0.00125	CcSEcCtD
Amiloride—Chest pain—Epirubicin—uterine cancer	0.000272	0.00125	CcSEcCtD
Amiloride—SLC22A1—Neuronal System—ABCC9—uterine cancer	0.000271	0.00267	CbGpPWpGaD
Amiloride—Vertigo—Doxorubicin—uterine cancer	0.000266	0.00122	CcSEcCtD
Amiloride—SLC9A1—Metabolism—POLD1—uterine cancer	0.000265	0.00261	CbGpPWpGaD
Amiloride—Confusional state—Epirubicin—uterine cancer	0.000263	0.00121	CcSEcCtD
Amiloride—Palpitations—Doxorubicin—uterine cancer	0.000261	0.0012	CcSEcCtD
Amiloride—Cough—Doxorubicin—uterine cancer	0.000258	0.00119	CcSEcCtD
Amiloride—Shock—Epirubicin—uterine cancer	0.000256	0.00118	CcSEcCtD
Amiloride—SLC9A1—Disease—DCN—uterine cancer	0.000256	0.00253	CbGpPWpGaD
Amiloride—Arthralgia—Doxorubicin—uterine cancer	0.000252	0.00116	CcSEcCtD
Amiloride—Chest pain—Doxorubicin—uterine cancer	0.000252	0.00116	CcSEcCtD
Amiloride—Anorexia—Epirubicin—uterine cancer	0.000248	0.00114	CcSEcCtD
Amiloride—SLC9A1—Metabolism—AKR1C1—uterine cancer	0.000248	0.00244	CbGpPWpGaD
Amiloride—Confusional state—Doxorubicin—uterine cancer	0.000243	0.00112	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000237	0.00109	CcSEcCtD
Amiloride—Shock—Doxorubicin—uterine cancer	0.000237	0.00109	CcSEcCtD
Amiloride—Insomnia—Epirubicin—uterine cancer	0.000236	0.00108	CcSEcCtD
Amiloride—Paraesthesia—Epirubicin—uterine cancer	0.000234	0.00108	CcSEcCtD
Amiloride—Dyspnoea—Epirubicin—uterine cancer	0.000232	0.00107	CcSEcCtD
Amiloride—Somnolence—Epirubicin—uterine cancer	0.000232	0.00107	CcSEcCtD
Amiloride—Anorexia—Doxorubicin—uterine cancer	0.00023	0.00106	CcSEcCtD
Amiloride—Dyspepsia—Epirubicin—uterine cancer	0.000229	0.00105	CcSEcCtD
Amiloride—SLC9A1—Disease—AKR1C3—uterine cancer	0.000228	0.00225	CbGpPWpGaD
Amiloride—Decreased appetite—Epirubicin—uterine cancer	0.000227	0.00104	CcSEcCtD
Amiloride—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000225	0.00103	CcSEcCtD
Amiloride—Fatigue—Epirubicin—uterine cancer	0.000225	0.00103	CcSEcCtD
Amiloride—Pain—Epirubicin—uterine cancer	0.000223	0.00102	CcSEcCtD
Amiloride—Constipation—Epirubicin—uterine cancer	0.000223	0.00102	CcSEcCtD
Amiloride—SLC9A1—Disease—HMGA1—uterine cancer	0.000222	0.00219	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—RRM2—uterine cancer	0.000221	0.00218	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.00022	0.00101	CcSEcCtD
Amiloride—Insomnia—Doxorubicin—uterine cancer	0.000218	0.001	CcSEcCtD
Amiloride—Paraesthesia—Doxorubicin—uterine cancer	0.000217	0.000996	CcSEcCtD
Amiloride—Dyspnoea—Doxorubicin—uterine cancer	0.000215	0.000988	CcSEcCtD
Amiloride—Feeling abnormal—Epirubicin—uterine cancer	0.000215	0.000987	CcSEcCtD
Amiloride—SLC9A1—Metabolism—DCN—uterine cancer	0.000215	0.00211	CbGpPWpGaD
Amiloride—Somnolence—Doxorubicin—uterine cancer	0.000214	0.000986	CcSEcCtD
Amiloride—Gastrointestinal pain—Epirubicin—uterine cancer	0.000213	0.00098	CcSEcCtD
Amiloride—Dyspepsia—Doxorubicin—uterine cancer	0.000212	0.000976	CcSEcCtD
Amiloride—Decreased appetite—Doxorubicin—uterine cancer	0.00021	0.000964	CcSEcCtD
Amiloride—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000208	0.000957	CcSEcCtD
Amiloride—Fatigue—Doxorubicin—uterine cancer	0.000208	0.000956	CcSEcCtD
Amiloride—Pain—Doxorubicin—uterine cancer	0.000206	0.000948	CcSEcCtD
Amiloride—Constipation—Doxorubicin—uterine cancer	0.000206	0.000948	CcSEcCtD
Amiloride—Abdominal pain—Epirubicin—uterine cancer	0.000206	0.000947	CcSEcCtD
Amiloride—SLC9A1—Disease—FBXW7—uterine cancer	0.000203	0.002	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—CYP11A1—uterine cancer	0.000202	0.00199	CbGpPWpGaD
Amiloride—Feeling abnormal—Doxorubicin—uterine cancer	0.000199	0.000914	CcSEcCtD
Amiloride—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000197	0.000907	CcSEcCtD
Amiloride—SLC9A1—Metabolism—AKR1C3—uterine cancer	0.000191	0.00188	CbGpPWpGaD
Amiloride—Abdominal pain—Doxorubicin—uterine cancer	0.000191	0.000876	CcSEcCtD
Amiloride—Asthenia—Epirubicin—uterine cancer	0.000187	0.00086	CcSEcCtD
Amiloride—Pruritus—Epirubicin—uterine cancer	0.000184	0.000848	CcSEcCtD
Amiloride—Diarrhoea—Epirubicin—uterine cancer	0.000178	0.00082	CcSEcCtD
Amiloride—Asthenia—Doxorubicin—uterine cancer	0.000173	0.000795	CcSEcCtD
Amiloride—Dizziness—Epirubicin—uterine cancer	0.000172	0.000792	CcSEcCtD
Amiloride—Pruritus—Doxorubicin—uterine cancer	0.000171	0.000784	CcSEcCtD
Amiloride—Vomiting—Epirubicin—uterine cancer	0.000166	0.000762	CcSEcCtD
Amiloride—Diarrhoea—Doxorubicin—uterine cancer	0.000165	0.000759	CcSEcCtD
Amiloride—Rash—Epirubicin—uterine cancer	0.000164	0.000756	CcSEcCtD
Amiloride—Dermatitis—Epirubicin—uterine cancer	0.000164	0.000755	CcSEcCtD
Amiloride—Headache—Epirubicin—uterine cancer	0.000163	0.000751	CcSEcCtD
Amiloride—Dizziness—Doxorubicin—uterine cancer	0.000159	0.000733	CcSEcCtD
Amiloride—SLC9A1—Disease—CDKN2B—uterine cancer	0.000159	0.00157	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000156	0.00154	CbGpPWpGaD
Amiloride—Nausea—Epirubicin—uterine cancer	0.000155	0.000712	CcSEcCtD
Amiloride—Vomiting—Doxorubicin—uterine cancer	0.000153	0.000705	CcSEcCtD
Amiloride—Rash—Doxorubicin—uterine cancer	0.000152	0.000699	CcSEcCtD
Amiloride—Dermatitis—Doxorubicin—uterine cancer	0.000152	0.000698	CcSEcCtD
Amiloride—Headache—Doxorubicin—uterine cancer	0.000151	0.000695	CcSEcCtD
Amiloride—SLC9A1—Metabolism—CYP19A1—uterine cancer	0.000149	0.00147	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—STK11—uterine cancer	0.000149	0.00147	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000146	0.00143	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SMAD3—uterine cancer	0.000145	0.00143	CbGpPWpGaD
Amiloride—Nausea—Doxorubicin—uterine cancer	0.000143	0.000659	CcSEcCtD
Amiloride—SLC9A1—Disease—FGFR2—uterine cancer	0.000139	0.00137	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MTHFR—uterine cancer	0.000134	0.00132	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—EP300—uterine cancer	0.000132	0.0013	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—VEGFA—uterine cancer	0.000125	0.00123	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—NRAS—uterine cancer	0.000124	0.00122	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—MTHFR—uterine cancer	0.000112	0.0011	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—KRAS—uterine cancer	0.000106	0.00105	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—SRD5A2—uterine cancer	0.000101	0.000997	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—NDUFB11—uterine cancer	0.000101	0.000997	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—PIK3CA—uterine cancer	9.77e-05	0.000962	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—uterine cancer	9.45e-05	0.000931	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—NDUFB11—uterine cancer	9.44e-05	0.000929	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—SRD5A2—uterine cancer	9.44e-05	0.000929	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—HRAS—uterine cancer	9.04e-05	0.00089	CbGpPWpGaD
Amiloride—SLC9A1—Disease—ERBB2—uterine cancer	8.71e-05	0.000858	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CDKN1B—uterine cancer	8.07e-05	0.000795	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—AKT1—uterine cancer	7.98e-05	0.000786	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CTNNB1—uterine cancer	7.62e-05	0.000751	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTEN—uterine cancer	7.43e-05	0.000732	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKR1B1—uterine cancer	7.32e-05	0.000721	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—STAR—uterine cancer	7.32e-05	0.000721	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EP300—uterine cancer	7.09e-05	0.000698	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—STAR—uterine cancer	6.82e-05	0.000672	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKR1B1—uterine cancer	6.82e-05	0.000672	CbGpPWpGaD
Amiloride—SLC9A1—Disease—NRAS—uterine cancer	6.63e-05	0.000653	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTEN—uterine cancer	6.22e-05	0.000613	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—EP300—uterine cancer	5.93e-05	0.000584	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—POLD1—uterine cancer	5.74e-05	0.000566	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KRAS—uterine cancer	5.71e-05	0.000562	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKR1C1—uterine cancer	5.37e-05	0.000529	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—POLD1—uterine cancer	5.35e-05	0.000527	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PIK3CA—uterine cancer	5.24e-05	0.000516	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKR1C1—uterine cancer	5.01e-05	0.000493	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HRAS—uterine cancer	4.85e-05	0.000478	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—RRM2—uterine cancer	4.79e-05	0.000472	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—DCN—uterine cancer	4.65e-05	0.000458	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—HRAS—uterine cancer	4.56e-05	0.000449	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—RRM2—uterine cancer	4.46e-05	0.00044	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PIK3CA—uterine cancer	4.39e-05	0.000432	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CYP11A1—uterine cancer	4.38e-05	0.000431	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—DCN—uterine cancer	4.33e-05	0.000427	CbGpPWpGaD
Amiloride—SLC9A1—Disease—AKT1—uterine cancer	4.28e-05	0.000422	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—HRAS—uterine cancer	4.25e-05	0.000418	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKR1C3—uterine cancer	4.14e-05	0.000407	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CYP11A1—uterine cancer	4.08e-05	0.000402	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKR1C3—uterine cancer	3.85e-05	0.00038	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—AKT1—uterine cancer	3.59e-05	0.000353	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—HRAS—uterine cancer	3.49e-05	0.000344	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—HRAS—uterine cancer	3.25e-05	0.00032	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CYP19A1—uterine cancer	3.22e-05	0.000317	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—STK11—uterine cancer	3.22e-05	0.000317	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—STK11—uterine cancer	3e-05	0.000296	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CYP19A1—uterine cancer	3e-05	0.000296	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—MTHFR—uterine cancer	2.42e-05	0.000238	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—MTHFR—uterine cancer	2.26e-05	0.000222	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTEN—uterine cancer	1.35e-05	0.000133	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—EP300—uterine cancer	1.28e-05	0.000127	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTEN—uterine cancer	1.26e-05	0.000124	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—EP300—uterine cancer	1.2e-05	0.000118	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PIK3CA—uterine cancer	9.5e-06	9.36e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PIK3CA—uterine cancer	8.86e-06	8.72e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKT1—uterine cancer	7.76e-06	7.64e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKT1—uterine cancer	7.23e-06	7.13e-05	CbGpPWpGaD
